Rachel M Wake1,2, Erika Britz1, Charlotte Sriruttan1,3, Ivy Rukasha1, Tanvier Omar3, David C Spencer4,5, Jeremy S Nel4, Sello Mashamaite5, Adeboye Adelekan6, Tom M Chiller7, Joseph N Jarvis8,9,10, Thomas S Harrison2, Nelesh P Govender1,3,11. 1. Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases. 2. Institute for Infection and Immunity, St George's University of London. 3. School of Pathology, Faculty of Health Sciences, University of the Witwatersrand. 4. Helen Joseph Hospital, Johannesburg, South Africa. 5. Right to Care, Johannesburg, South Africa. 6. Centers for Disease Control and Prevention, Pretoria. 7. Centers for Disease Control and Prevention, Atlanta, Georgia. 8. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United Kingdom. 9. Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 10. Botswana-UPenn Partnership, Gaborone, Botswana. 11. Division of Medical Microbiology, Faculty of Health Sciences, University of Cape Town, South Africa.
Abstract
Background: High mortality rates among asymptomatic cryptococcal antigen (CrAg)-positive patients identified through CrAg screening, despite preemptive fluconazole treatment, may be due to undiagnosed cryptococcal meningitis. Methods: Symptoms were reviewed in CrAg-positive patients identified by screening 19233 individuals with human immunodeficiency virus infection and CD4 cell counts <100/µL at 17 clinics and 3 hospitals in Johannesburg from September 2012 until September 2015, and at 2 hospitals until June 2016. Cerebrospinal fluid samples from 90 of 254 asymptomatic patients (35%) and 78 of 173 (45%) with headache only were analyzed for cryptococcal meningitis, considered present if Cryptococcus was identified by means of India ink microscopy, culture, or CrAg test. CrAg titers were determined with stored blood samples from 62 of these patients. The associations between blood CrAg titer, concurrent cryptococcal meningitis, and mortality rate were assessed. Results: Cryptococcal meningitis was confirmed in 34% (95% confidence interval, 25%-43%; 31 of 90) of asymptomatic CrAg-positive patients and 90% (81%-96%; 70 of 78) with headache only. Blood CrAg titer was significantly associated with concurrent cryptococcal meningitis in asymptomatic patients (P < .001) and patients with headache only (P = .003). The optimal titer for predicting cryptococcal meningitis was >160 (sensitivity, 88.2%; specificity, 82.1%); the odds ratio for concurrent cryptococcal meningitis was 34.5 (95% confidence interval, 8.3-143.1; P < .001). Conclusions: About a third of asymptomatic CrAg-positive patients have concurrent cryptococcal meningitis. More effective clinical assessment strategies and antifungal regimens are required for CrAg-positive patients, including investigation for cryptococcal meningitis irrespective of symptoms. Where it is not possible to perform lumbar punctures in all CrAg-positive patients, blood CrAg titers should be used to target those most at risk of cryptococcal meningitis.
Background: High mortality rates among asymptomatic cryptococcal antigen (CrAg)-positive patients identified through CrAg screening, despite preemptive fluconazole treatment, may be due to undiagnosed cryptococcal meningitis. Methods: Symptoms were reviewed in CrAg-positive patients identified by screening 19233 individuals with human immunodeficiency virus infection and CD4 cell counts <100/µL at 17 clinics and 3 hospitals in Johannesburg from September 2012 until September 2015, and at 2 hospitals until June 2016. Cerebrospinal fluid samples from 90 of 254 asymptomatic patients (35%) and 78 of 173 (45%) with headache only were analyzed for cryptococcal meningitis, considered present if Cryptococcus was identified by means of India ink microscopy, culture, or CrAg test. CrAg titers were determined with stored blood samples from 62 of these patients. The associations between blood CrAg titer, concurrent cryptococcal meningitis, and mortality rate were assessed. Results:Cryptococcal meningitis was confirmed in 34% (95% confidence interval, 25%-43%; 31 of 90) of asymptomatic CrAg-positive patients and 90% (81%-96%; 70 of 78) with headache only. Blood CrAg titer was significantly associated with concurrent cryptococcal meningitis in asymptomatic patients (P < .001) and patients with headache only (P = .003). The optimal titer for predicting cryptococcal meningitis was >160 (sensitivity, 88.2%; specificity, 82.1%); the odds ratio for concurrent cryptococcal meningitis was 34.5 (95% confidence interval, 8.3-143.1; P < .001). Conclusions: About a third of asymptomatic CrAg-positive patients have concurrent cryptococcal meningitis. More effective clinical assessment strategies and antifungal regimens are required for CrAg-positive patients, including investigation for cryptococcal meningitis irrespective of symptoms. Where it is not possible to perform lumbar punctures in all CrAg-positive patients, blood CrAg titers should be used to target those most at risk of cryptococcal meningitis.
Authors: Cathy A Petti; Christopher R Polage; Thomas C Quinn; Allan R Ronald; Merle A Sande Journal: Clin Infect Dis Date: 2005-12-20 Impact factor: 9.079
Authors: Shikha W Kapoor; Kinanga A Magambo; Samuel E Kalluvya; Daniel W Fitzgerald; Robert N Peck; Jennifer A Downs Journal: AIDS Date: 2015-11-28 Impact factor: 4.177
Authors: Sayoki Mfinanga; Duncan Chanda; Sokoine L Kivuyo; Lorna Guinness; Christian Bottomley; Victoria Simms; Carol Chijoka; Ayubu Masasi; Godfather Kimaro; Bernard Ngowi; Amos Kahwa; Peter Mwaba; Thomas S Harrison; Saidi Egwaga; Shabbar Jaffar Journal: Lancet Date: 2015-03-10 Impact factor: 79.321
Authors: Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Bahati Mk Wajanga; Samuel Kalluvya; Jennifer A Downs; Warren D Johnson; Daniel W Fitzgerald; Robert N Peck Journal: J Int AIDS Soc Date: 2011-10-11 Impact factor: 5.396
Authors: Peter R Kisenge; Alexander T Hawkins; Venance P Maro; John P D McHele; Ndealilia S Swai; Andreas Mueller; Eric R Houpt Journal: BMC Infect Dis Date: 2007-05-10 Impact factor: 3.090
Authors: Emilio Letang; Matthias C Müller; Alex J Ntamatungiro; Namvua Kimera; Diana Faini; Hansjakob Furrer; Manuel Battegay; Marcel Tanner; Christoph Hatz; David R Boulware; Tracy R Glass Journal: Open Forum Infect Dis Date: 2015-04-02 Impact factor: 3.835
Authors: Nicky Longley; Joseph Nicholas Jarvis; Graeme Meintjes; Andrew Boulle; Anna Cross; Nicola Kelly; Nelesh P Govender; Linda-Gail Bekker; Robin Wood; Thomas S Harrison Journal: Clin Infect Dis Date: 2015-11-12 Impact factor: 9.079
Authors: Mark W Tenforde; Thandi Milton; Ikanyeng Rulaganyang; Charles Muthoga; Leabaneng Tawe; Tom Chiller; Gregory Greene; Alexander Jordan; Christopher G Williams; Leah Owen; Tshepo B Leeme; Amber Boose; Julia Ngidi; Madisa Mine; Joseph N Jarvis Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 9.079
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Kieren A Marr; Yifei Sun; Andrej Spec; Na Lu; Anil Panackal; John Bennett; Peter Pappas; Darin Ostrander; Kausik Datta; Sean X Zhang; Peter R Williamson Journal: Clin Infect Dis Date: 2020-01-02 Impact factor: 9.079
Authors: Rachel M Wake; Joseph N Jarvis; Thomas S Harrison; Nelesh P Govender Journal: J Acquir Immune Defic Syndr Date: 2018-08-15 Impact factor: 3.731
Authors: Adriana Paulino Silva; Carolina Toniolo Zenatti; Claudia Figueiredo-Mello; Marinella Della Negra; Anna S Levin; David R Boulware; José Ernesto Vidal Journal: Int J STD AIDS Date: 2020-02-23 Impact factor: 1.359